CRISPR Therapy Tackles Gut Bacteria
SNIPR Biome published final positive results from its Phase 1 trial of SNIPR001, a CRISPR-based therapy designed to selectively target and kill E. coli in the gut. As the first-ever randomized, placebo-controlled trial of its kind, the results are a key proof-of-concept for using synthetic biology to precisely edit the microbiome.
SNIPR001 is a cocktail of four different bacteriophages—viruses that naturally prey on bacteria—which have been armed with CRISPR-Cas systems. These engineered phages are designed to act as a precision antibiotic, hunting down and slicing up the DNA of specific *E. coli* strains while leaving the beneficial parts of the gut microbiome intact. The therapy targets a critical unmet need for patients with blood cancers undergoing stem cell transplants. These patients often have their immune systems wiped out by chemotherapy, making them highly vulnerable to their own gut bacteria, like *E. coli*, crossing into the bloodstream and causing deadly infections. The company behind the therapy, Denmark-based SNIPR Biome, has raised over $139 million and is supported by global health partners like CARB-X and the Bill & Melinda Gates Foundation, who are focused on combating antimicrobial resistance. The U.S. Food and Drug Administration (FDA) has granted SNIPR001 a "Fast Track" designation to speed up its development and review process. Developing this technology showcases the "tech" career track in life sciences. Synthetic biologists and bioinformaticians design such therapies, requiring advanced degrees (M.S. or Ph.D.) in fields like molecular biology or computational biology. Their work involves lab-based genetic engineering and using programming skills to analyze massive biological datasets. Running the clinical trial represents the patient-facing track. Physician-scientists (MD/PhDs) and clinical research coordinators manage the study, ensure patient safety, and collect the data that proves if the drug works. This path requires a deep understanding of human disease, patient care, and the strict regulations governing new medicines. Ultimately, this single trial involves two distinct career worlds. In one, computational biologists
